Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dexamethasone/Pancreatic Clamp P&F
NCT06126354 · Columbia University · PHASE1 · withdrawn · last registry update 2024-07-10 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Investigators' scientific priorities shifted.” | – | Registry record, Columbia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against INSR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-02Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04880850)
- 2025-06-24Results posted on the registry: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05463744)
- 2025-06-12Results posted on the registry: Novo Nordisk A/S, insulin icodec + insulin degludec (NCT04848480)
- 2025-06-12Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT04460885)
- 2025-06-03Results posted on the registry: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05275400)
- 2025-05-16Results posted on the registry: Eli Lilly and Company, Insulin Efsitora Alfa + Insulin Degludec (NCT05362058)
- 2025-04-03Results posted on the registry: Novo Nordisk A/S, IcoSema + Insulin icodec (NCT05352815)
- 2025-03-17Results posted on the registry: University of Minnesota, novolog insulin + levemir insulin (NCT02496780)
- 2025-03-17Also stopped (terminated): University of Minnesota, novolog insulin + levemir insulin (NCT02496780)
- 2025-02-20Results posted on the registry: Novo Nordisk A/S, Insulin degludec + Insulin Icodec (NCT04770532)
- 2025-01-17Results posted on the registry: Novo Nordisk A/S, IcoSema + Semaglutide 1 mg (NCT05259033)
- 2025-01-10Phase 3 first posted: Gan & Lee Pharmaceuticals., GZR4 + insulin degludec (NCT06767748)
- 2024-12-04Results posted on the registry: Novo Nordisk A/S, Insulin icodec + Placebo insulin icodec (NCT04795531)
- 2024-11-20Also stopped (terminated): Astellas Pharma Inc, OSI-906 + Placebo (NCT01101906)
- 2024-10-30Results posted on the registry: Sanofi, Insulin glargine/Lixisenatide + IDegAsp (NCT05413369)
- 2024-10-18Results posted on the registry: Mannkind Corporation, Afrezza (insulin human) Inhalation Powder + insulin degludec (NCT05243628)
- 2024-10-01Phase 3 first posted: Loyola University, Insulin glargine + insulin NPH (NCT06619301)
- 2024-09-19Phase 3 first posted: University of Campinas, Brazil, NPH insulin 50 IU/mL eye drops + 0.5% methylcellulose eye drops (placebo) (NCT06601101)
- 2024-09-05Results posted on the registry: Sanofi, Insulin glargine 300 U/mL + Insulin degludec 100 U/mL (NCT05552859)
- 2024-08-19Phase 3 first posted: Tonghua Dongbao Pharmaceutical Co.,Ltd, Insulin Degludec/liraglutide Injection + XULTOPHY® (NCT06559722)
- 2024-07-29Results posted on the registry: The Cleveland Clinic, Semaglutide + Insulin Degludec (NCT04538352)
- 2024-04-02Phase 3 first posted: Novo Nordisk A/S, Insulin icodec + Insulin glargine (NCT06340854)
- 2024-03-20Results posted on the registry: Novo Nordisk A/S, Faster aspart + Insulin aspart (NCT04588259)
- 2024-02-28Results posted on the registry: University of Washington, Insulin Degludec + Insulin Glargine (NCT04623086)
- 2024-02-21Phase 3 first posted: Novo Nordisk A/S, IcoSema + Insulin glargine (NCT06269107)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision